IMA: חוב לטווח קצר להון עצמי Ikena Oncology, Inc.

This chart shows the current share price of ImageneBio Inc (IMA) on the GURU.Markets platform at 0.01. High R&D expenditures and patent protection create significant barriers to entry for new players within the stringent FDA regulatory environment. The business relies on cash burn due to a lack of sales, and its success depends on the results of targeted therapy trials, which eliminates price competition.

This indicator measures the proportion of short-term liabilities relative to equity, determining the extent of the company's dependence on rapid debt refinancing during periods of market volatility. For ImageneBio Inc (IMA), which is establishing a long-term patent monopoly in cancer immunotherapy, the short-term debt-to-equity ratio demonstrates financial stability amidst prolonged clinical trials, minimizing liquidity risk prior to market entry.